Reshma L. Mahtani, DO

The use of chemotherapy trended toward improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.

Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.

Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.

An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.

Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.

Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.

A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.

The rationale for treating early-stage HR+ breast cancer with extended adjuvant therapy and factors that impact treatment selection.